NCT02687971View on ClinicalTrials.gov

Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨

PHASE2CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 10, 2019

Study Completion Date

September 10, 2019

Conditions

Cutaneous Leishmaniasis

Interventions

DRUG

Miltefosine

Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.

Trial Locations (2)

Unknown

Programa de Estudios y Control de Enfermedades Tropicales (PECET), Universidad de Antioquia, Medellín

IMT Alexander Von Humboldt, Lima

All Listed Sponsors

lead

Drugs for Neglected Diseases

OTHER

NCT02687971 - Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ | Biotech Hunter | Biotech Hunter